How it works:
Lenvatinib targets and blocks multiple tyrosine kinase receptors including VEGFR, FGFR, PDGFR, RET and KIT. It suppresses tumour proliferation and angiogenesis, thereby limiting blood supply to malignant cells and slowing disease progression.
Recommended for:
Patients with radioactive iodine-refractory differentiated thyroid carcinoma
Individuals with hepatocellular carcinoma
Patients with renal cell carcinoma (as part of combination therapy)
Those requiring initial or adjusted dosing for precision therapy
Differentiated thyroid cancer (DTC), refractory to radioactive iodine
Hepatocellular carcinoma
Advanced renal cell carcinoma (in combination therapy)
The medication is taken orally once daily, with or without food. Dosage is determined individually by an oncologist, and LENVAT 4mg can be used for dose adjustments or as part of a stepped treatment protocol. It may be combined with other targeted agents for enhanced efficacy.
Hypersensitivity to lenvatinib or excipients
Pregnancy and breastfeeding
Severe liver or kidney dysfunction
Uncontrolled hypertension
Recent GI bleeding or perforation
Hypertension
Fatigue, weight loss
Diarrhoea, appetite loss
Proteinuria
Liver and kidney function disturbances
Rash, skin irritation
Headache, joint and muscle pain
